- Home
- SVRE vs KZIA Comparison
SVRE vs KZIA Comparison
Compare SVRE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- KZIA
- Stock Information
- Founded
- SVRE 2014
- KZIA 1994
- Country
- SVRE Israel
- KZIA Australia
- Employees
- SVRE N/A
- KZIA N/A
- Industry
- SVRE
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SVRE
- KZIA Health Care
- Exchange
- SVRE Nasdaq
- KZIA Nasdaq
- Market Cap
- SVRE 883.2K
- KZIA 5.1M
- IPO Year
- SVRE 2022
- KZIA 1999
- Fundamental
- Price
- SVRE $1.25
- KZIA $3.80
- Analyst Decision
- SVRE
- KZIA Strong Buy
- Analyst Count
- SVRE 0
- KZIA 2
- Target Price
- SVRE N/A
- KZIA $57.50
- AVG Volume (30 Days)
- SVRE 139.6K
- KZIA 20.6K
- Earning Date
- SVRE 03-21-2025
- KZIA 06-10-2025
- Dividend Yield
- SVRE N/A
- KZIA N/A
- EPS Growth
- SVRE N/A
- KZIA N/A
- EPS
- SVRE N/A
- KZIA N/A
- Revenue
- SVRE $462,071.00
- KZIA $1,655,324.00
- Revenue This Year
- SVRE $458.76
- KZIA N/A
- Revenue Next Year
- SVRE $106.57
- KZIA N/A
- P/E Ratio
- SVRE N/A
- KZIA N/A
- Revenue Growth
- SVRE N/A
- KZIA 248000.00
- 52 Week Low
- SVRE $1.17
- KZIA $2.86
- 52 Week High
- SVRE $170.36
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- SVRE 31.70
- KZIA 54.11
- Support Level
- SVRE $1.20
- KZIA $3.24
- Resistance Level
- SVRE $1.42
- KZIA $3.75
- Average True Range (ATR)
- SVRE 0.15
- KZIA 0.28
- MACD
- SVRE 0.02
- KZIA 0.05
- Stochastic Oscillator
- SVRE 9.88
- KZIA 74.60
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.